Jason Meggs - Syneos Health Interim CFO, Executive Vice President
| SYNHDelisted Stock | USD 42.31 0.07 0.17% |
President
Mr. Jason Meggs is Chief Financial Officer of the company. Prior to his appointment to this role, he served as Executive Vice President and CFO of the Commercial Solutions segment of the Company from August 2017 to February 2018. He also previously served as Executive Vice President, Oncology Operations of the Company from January 2017 to August 2017 and Senior Vice President, Business Finance of the Company from 2014 to 2016. Prior to joining the Company, Mr. Meggs was Global Vice President, Internal Audit, at Quintiles Transnational Corporation from 2013 to 2014 and held a number of finance roles at Quintiles from 2005 to 2013. He began his career as an auditor with Deloitte Touche LLP and Arthur Anderson LLP, and is a certified public accountant. He received his BS in Business Administration degree with a Major in Accounting from Western Carolina University. since 2019.
| Age | 47 |
| Tenure | 5 years |
| Phone | 919 876 9300 |
| Web | https://www.syneoshealth.com |
Syneos Health Management Efficiency
The company has return on total asset (ROA) of 0.0263 % which means that it generated a profit of $0.0263 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0209 %, meaning that it created $0.0209 on every $100 dollars invested by stockholders. Syneos Health's management efficiency ratios could be used to measure how well Syneos Health manages its routine affairs as well as how well it operates its assets and liabilities.Syneos Health currently holds 2.9 B in liabilities with Debt to Equity (D/E) ratio of 0.93, which is about average as compared to similar companies. Syneos Health has a current ratio of 1.08, suggesting that it may have difficulties to pay its financial obligations when due. Note, when we think about Syneos Health's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Ronald Bruehlman | IQVIA Holdings | 63 | |
| Peter Wilkinson | Laboratory of | 53 | |
| Brian Mi | IQVIA Holdings | 58 | |
| Jonathan Sheldon | Qiagen NV | 52 | |
| Michael McDonnell | IQVIA Holdings | 55 | |
| Mital Patel | RadNet Inc | 38 | |
| Sandra Vaart | Laboratory of | 64 | |
| Joseph LaPlume | Charles River Laboratories | 50 | |
| Rob Kotchie | IQVIA Holdings | N/A | |
| Michael Knell | Charles River Laboratories | 47 | |
| Lance Berberian | Laboratory of | 61 | |
| William Barbo | Charles River Laboratories | 63 | |
| Kevin Knightly | IQVIA Holdings | 63 | |
| Richard III | IQVIA Holdings | 61 | |
| Eric Sherbet | IQVIA Holdings | 60 | |
| Joseph Shrawder | Sotera Health Co | N/A | |
| Thomas Schweins | Qiagen NV | N/A | |
| Nilton Paletta | IQVIA Holdings | N/A | |
| Wendy Stewart | IQVIA Holdings | N/A | |
| Walter Staub | IQVIA Holdings | 57 | |
| Riaz MBA | Sotera Health Co | 54 | |
Management Performance
| Return On Equity | 0.0209 | |||
| Return On Asset | 0.0263 |
Syneos Health Leadership Team
Elected by the shareholders, the Syneos Health's board of directors comprises two types of representatives: Syneos Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Syneos. The board's role is to monitor Syneos Health's management team and ensure that shareholders' interests are well served. Syneos Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Syneos Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jason Meggs, Interim CFO, Executive Vice President | ||
| Jonathan Olefson, General Counsel, Corporate Secretary | ||
| Michael Brooks, Chief Officer | ||
| Judith MD, Chief Officer | ||
| Alistair Macdonald, CEO, Director | ||
| Ronnie Speight, Vice President Investor Relations | ||
| Baba Shetty, Pres Solutions | ||
| Michelle Keefe, CEO Director | ||
| Larry Pickett, Chief Officer | ||
| Donna Kralowetz, Sr Officer |
Syneos Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Syneos Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0209 | |||
| Return On Asset | 0.0263 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | 0.06 % | |||
| Current Valuation | 7.23 B | |||
| Shares Outstanding | 103.72 M | |||
| Shares Owned By Insiders | 0.48 % | |||
| Shares Owned By Institutions | 94.74 % | |||
| Number Of Shares Shorted | 6.76 M | |||
| Price To Earning | 18.05 X |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Other Consideration for investing in Syneos Stock
If you are still planning to invest in Syneos Health check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Syneos Health's history and understand the potential risks before investing.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |